Participants in dementia prevention research motivated by altruism

October 5, 2018, University of California - San Diego

Researchers at University of California San Diego School of Medicine, with collaborators across the country, report that people who participate in dementia prevention trials are primarily motivated by altruism and pleased to help.

The findings are published in the October 5 issue of Alzheimer's & Dementia.

"For the most part, people appeared satisfied with their experience in a clinical trial," said first author Mary Sano, Ph.D., professor of psychiatry and director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine in New York City. "A big takeaway is how altruism and giving back are important to participants. We were also intrigued by the desire for increased social interactions."

The study surveyed 422 non-demented participants, age 75 and older, in the Home-Based Assessment (HBA) study at 27 sites across the country. The HBA study—a four-year, longitudinal study using novel technologies to determine the feasibility of assessing cognitively normal in their own homes—was coordinated by the Alzheimer's Disease Cooperative Study (ADCS), an initiative of the National Institute on Aging based at UC San Diego School of Medicine.

Almost 6 million Americans are currently living with Alzheimer's disease (AD), according to the Alzheimer's Association, with an American developing the disease every 65 seconds. By 2050, the number of persons with AD is projected to rise to nearly 14 million, making the need for research critical.

Yet little is known about the factors affecting the motivation and satisfaction of participants in dementia prevention trials, say experts. Beyond a motivation to help, the new study was an attempt to determine how future clinical trials might be made more attractive and effective. The HBA study involved various levels of , such as mail-in questionnaires, live telephone interviews, automated telephone calls with and an internet-connected, home-sited computer kiosk with responses captured via automated speech recognition.

Researchers found that trial participants preferred staff-administered assessments more than automated technologies; greater opportunity to challenge and improve their own mental function (such as a wider variety of activities during testing); and increased interaction with both study staff and other, older adults. They also sought more personal feedback from researchers as the trial progressed.

Sano said it wasn't surprising that participants became bored with repetitive tasks and frustrated by inevitable equipment glitches.

"It's important to understand because it's common for new trials to have more technology and less human interaction," she said. "While advanced technology is clearly essential, we also must remember that people want to feel valued for their own ideas and personalities."

Co-author Jeffrey Kaye, MD, professor of neurology at Oregon Health and Science University and director of both the Layton Aging and Alzheimer's Disease Center and the Oregon Center for Aging and Technology, suggested technology should be used with participant comfort in mind.

"To maximize the advantages that technologies can bring to clinical , it is important to ensure that devices or interactions with technology are integrated into participants' everyday lives. Ideally, the technology works in the background and is as unobtrusive as possible. If there are needed interactions, these must be engaging and minimally burdensome, especially when studies may be conducted over many years."

Senior author Howard Feldman, MD, professor of neurosciences at UC San Diego School of Medicine, and clinical neurologist and director of the ADCS said the findings should inform and improve future study design.

"By listening to the concerns and suggestions of our participants, we build better, more effective studies in the future," he said. "It's good to know that participants are feeling the spirit of altruism in this work, as we are essentially relying on successful expansion of this community effort to address the ever increasing size and challenges of Alzheimer's disease.

"It is incumbent on us to listen and plan accordingly. It is also important to note, and not to underestimate, the human element described in this research. Direct human interaction seems to be an important contributor to participant engagement and retention. It is a reminder that human contact provides a benefit to these studies, supporting in a way that technology cannot."

Explore further: Time to rethink how we diagnose Alzheimer's disease

More information: Mary Sano et al. Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial, Alzheimer's & Dementia (2018). DOI: 10.1016/j.jalz.2018.05.016

Related Stories

Time to rethink how we diagnose Alzheimer's disease

October 3, 2018
With all the focus on Alzheimer disease in recent years as a result of the aging population, what have we learned? A symposium at The North American Menopause Society (NAMS) Annual Meeting in San Diego, October 3-6, will ...

Free online tool to accelerate Alzheimer's treatment created by USC and top medical groups

February 28, 2018
An online tool that helps older people monitor their brain health has been developed at the Keck School of Medicine of USC with other medical groups.

Evaluation and treatment of depression may reverse memory and cognitive difficulties

March 27, 2018
Individuals with worse depression and mood symptoms are more likely to develop Mild Cognitive Impairment (MCI) and to progress from MCI to dementia. Evaluation and treatment of symptoms of depression may improve or maintain ...

Population of Americans with Alzheimer's will more than double by 2060, study shows

December 7, 2017
About 15 million Americans will have either Alzheimer's dementia or mild cognitive impairment by 2060, up from approximately 6.08 million this year, according to a new study by researchers at the UCLA Fielding School of Public ...

Test lets volunteers check Alzheimer's risk, join clinical trials

January 31, 2018
People interested in helping test Alzheimer's drugs can volunteer and get their cognitive abilities monitored on a new website run by Alzheimer's researchers.

Decline in daily functioning related to decreased brain activity in Alzheimer's

August 12, 2014
Decline in daily functioning associated with Alzheimer's disease is related to alterations in activity in certain regions of the brain, according to a study published in the August 2014 issue of the Journal of Alzheimer's ...

Recommended for you

Does diabetes damage brain health?

December 14, 2018
(HealthDay)—Diabetes has been tied to a number of complications such as kidney disease, but new research has found that older people with type 2 diabetes can also have more difficulties with thinking and memory.

Amyloid pathology transmission in lab mice and historic medical treatments

December 13, 2018
A UCL-led study has confirmed that some vials of a hormone used in discontinued medical treatments contained seeds of a protein implicated in Alzheimer's disease, and are able to seed amyloid pathology in mice.

Study links slowed brainwaves to early signs of dementia

December 13, 2018
To turn back the clock on Alzheimer's disease, many researchers are seeking ways to effectively diagnose the neurodegenerative disorder earlier.

New discoveries predict ability to forecast dementia from single molecule

December 11, 2018
Scientists who recently identified the molecular start of Alzheimer's disease have used that finding to determine that it should be possible to forecast which type of dementia will develop over time—a form of personalized ...

Researchers classify Alzheimer's patients in six subgroups

December 5, 2018
Researchers studying Alzheimer's disease have created an approach to classify patients with Alzheimer's disease, a finding that may open the door for personalized treatments.

Neuroscientists pinpoint genes tied to dementia

December 3, 2018
A UCLA-led research team has identified genetic processes involved in the neurodegeneration that occurs in dementia—an important step on the path toward developing therapies that could slow or halt the course of the disease. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.